Title:Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Volume: 18
Issue: 3
Author(s): Mahmoud Abdelnabi *, Yehia Saleh , Abdallah Almaghraby, Hany Girgis and Fady Gerges
Affiliation:
- Cardiology and Angiology Unit, Clinical and Experimental Internal Medicine Department, Medical Research Institute,
Alexandria University, Alexandria, Egypt
Keywords:
Sacubitril/valsartan, heart failure with reduced ejection fraction (HFrEF), PARADIGM-HF, heart failure with preserved ejection fraction (HFpEF), ventricular arrhythmias, remodeling.
Abstract: Heart Failure (HF) is among the major causes of global morbidity as well as mortality.
Increased prevalence, frequent and prolonged hospitalization, rehospitalization, long-term consumption
of healthcare resources, absenteeism, and death upsurge the economic burden linked to
HF. For decades, Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor
Blockers (ARBs), Beta-Blockers (BBs), and mineralocorticoid receptor antagonists (MRA), have
remained the mainstay of the standard of care for HF management. Despite their proven efficacy
and cost-effectiveness, HF remains a global pandemic and is still increasing in prevalence. Sacubitril/
Valsartan (SAC/VAL) is an Angiotensin Receptor/Neprilysin Inhibitor (ARNI) that proved out
to be a game-changer drug in HF treatment. Recent data indicated that SAC/VAL is more efficient
and can improve the overall quality of life of HF patients with reduced ejection fraction (HFrEF)
with fewer side effects. It is now incorporated in the guidelines as an alternative to ACEIs or ARBs
to lower morbidity in addition to mortality in HFrEF patients. This review article will discuss the
current guidelines-approved indications and highlight the potential emerging indications, in addition
to the currently ongoing clinical trials that will expand the use of SAC/VAL.
